AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1 study is to evaluate the safety and potential efficacy of Gene
Mediated Cytotoxic Immunotherapy for pancreatic cancer. The approach uses an adenoviral
vector (disabled virus) engineered to express the Herpes thymidine kinase gene (AdV-tk),
followed by an antiherpetic prodrug, valacyclovir.